Vaccination
Effets secondaires
Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study, BMJ 2021; 373 doi: https://doi.org/10.1136/bmj.n1114 (Published 05 May 2021)
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination, M. Scully and Others, NEJM, DOI: 10.1056/NEJMoa2105385 | April 16, 2021
SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia, D.B. Cines and J.B. Bussel, NEJM, DOI: 10.1056/NEJMe2106315 | April 16, 2021
Efficacité
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, Al-Khatib HA, Smatti MK, Coyle P, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Abu-Raddad LJ. N Engl J Med. 2022 Jun 15. doi: 10.1056/NEJMoa2203965. Epub ahead of print. PMID: 35704396.
Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study. Gazit S, Saciuk Y, Perez G, Peretz A, Pitzer VE, Patalon T. BMJ. 2022 May 24;377:e071113. doi: 10.1136/bmj-2022-071113. PMID: 35609888; PMCID: PMC9127435.
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, Groome MJ, Huppert A, O'Brien KL, Smith PG, Wilder-Smith A, Zeger S, Deloria Knoll M, Patel MK. Lancet. 2022 Mar 5;399(10328):924-944. doi: 10.1016/S0140-6736(22)00152-0. Epub 2022 Feb 23. PMID: 35202601; PMCID: PMC8863502.
Three-dose vaccination elicits neutralising antibodies against omicron, Wu M et al. The Lancet, January 19, 2022DOI:https://doi.org/10.1016/S0140-6736(22)00092-7
SARS-CoV-2 variants of concern and variants under investigation in England, Technical briefing: Update on hospitalisation and vaccine effectiveness for Omicron VOC-21NOV-01 (B.1.1.529), UK Health security agency, 31 December 2021
Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants, David W. Eyre, B.M., B.Ch., D.Phil., Donald Taylor, M.Math., Mark Purver, Ph.D., David Chapman, Ph.D., Tom Fowler, Ph.D., Koen B. Pouwels, Ph.D., A. Sarah Walker, Ph.D., and Tim E.A. Peto, F.R.C.P., NEJM, January 5, 2022, DOI: 10.1056/NEJMoa2116597
Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection, I. Nemet and al, DOI: 10.1056/NEJMc2119358 | December 29, 2021
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa, S. Collie and al, DOI: 10.1056/NEJMc2119270 | December 29, 2021
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Tartof SY et coll. Lancet, 2021 publication avancée en ligne le 4 octobre. doi.org/10.1016/S0140-6736(21)02183-8
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant, J.L. Bernal et al, NEJM, July 21, 2021, DOI: 10.1056/NEJMoa2108891
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, Daniels R, Hobson P, Hatipoglu E, Ngai Y, Hussain S, Nicod J, Goldstone R, Ambrose K, Hindmarsh S, Beale R, Riddell A, Gamblin S, Howell M, Kassiotis G, Libri V, Williams B, Swanton C, Gandhi S, Bauer DL. Lancet. 2021 Jun 3:S0140-6736(21)01290-3. doi: 10.1016/S0140-6736(21)01290-3. Epub ahead of print. PMID: 34090624; PMCID: PMC8175044.
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant, S.A. Madhi and Others, N Engl J Med 2021; 384:1885-1898, DOI: 10.1056/NEJMoa2102214
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study, BMJ 2021; 373 doi: https://doi.org/10.1136/bmj.n1088 (Published 13 May 2021)
Pfizer/BioNTech say data suggests vaccine 94% effective in preventing asymptomatic infection, Reuters, MARCH 11, 2021
Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021, Early Release / March 29, 2021 / 70, MMWR, CDC
Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Lancet 2021;397:875–7. https://doi.org/10.1016/S0140-6736(21)00448-7, PMID:33610193
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, Padayachee SD, Dheda K, Barnabas SL, Bhorat QE, Briner C, Kwatra G, Ahmed K, Aley P, Bhikha S, Bhiman JN, Bhorat AE, du Plessis J, Esmail A, Groenewald M, Horne E, Hwa SH, Jose A, Lambe T, Laubscher M, Malahleha M, Masenya M, Masilela M, McKenzie S, Molapo K, Moultrie A, Oelofse S, Patel F, Pillay S, Rhead S, Rodel H, Rossouw L, Taoushanis C, Tegally H, Thombrayil A, van Eck S, Wibmer CK, Durham NM, Kelly EJ, Villafana TL, Gilbert S, Pollard AJ, de Oliveira T, Moore PL, Sigal A, Izu A; NGS-SA Group Wits–VIDA COVID Group.N Engl J Med. 2021 Mar 16. doi: 10.1056/NEJMoa2102214. Epub ahead of print. PMID: 33725432.
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine, NEJM, December 30, 2020, DOI: 10.1056/NEJMoa2035389
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, NEJM, December 10, 2020, DOI: 10.1056/NEJMoa2034577
Général
SARS-CoV-2 Vaccination — An Ounce (Actually, Much Less) of Prevention, NEJM, December 10, 2020, DOI: 10.1056/NEJMe2034717
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Lee, W.S., Wheatley, A.K., Kent, S.J. et al. Nat Microbiol 5, 1185–1191 (2020). https://doi.org/10.1038/s41564-020-00789-5
Placebo-Controlled Trials of Covid-19 Vaccines — Why We Still Need Them, WHO Ad Hoc Expert Group on the Next Steps for Covid-19 Vaccine Evaluation, NEJM, December 2, 2020
Avoiding pitfalls in the pursuit of a COVID-19 vaccine, Peeples L. PNAS April 14, 2020 117 (15) 8218-8221; first published March 30, 2020; https://doi.org/10.1073/pnas.2005456117, DOI: 10.1056/NEJMp2033538
Immunité naturelle
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers, Sheila F. Lumley, B.M., B.Ch., Denise O’Donnell, B.Sc., Nicole E. Stoesser, M.B., B.S., D.Phil., Philippa C. Matthews, F.R.C.P., D.Phil., Alison Howarth, Ph.D., Stephanie B. Hatch, Ph.D., Brian D. Marsden, D.Phil., Stuart Cox, Tim James, Ph.D., Fiona Warren, B.Sc., Liam J. Peck, D.Phil., Thomas G. Ritter, B.A., et al., for the Oxford University Hospitals Staff Testing Group*, NEJM, December 23, 2020, DOI: 10.1056/NEJMoa2034545
Decline in SARS-CoV-2 antibodies after mild infection among frontline health care personnel in a multistate hospital network — 12 States, Self WH et al. April–August 2020. MMWR Morb Mortal Wkly Rep 2020 Nov 27; 69:1762. (https://doi.org/10.15585/mmwr.mm6947a2)
Seasonal coronavirus protective immunity is short-lasting. Edridge, A.W.D., Kaczorowska, J., Hoste, A.C.R. et al. Nat Med (2020). https://doi.org/10.1038/s41591-020-1083-1